Table 4.
Patient characteristics with SLE only.
| The age of SLE onset | Comorbidity | Immunoserology | Actual clinical status | Therapy | Corticosteroids (mg PED) | SLICC |
|---|---|---|---|---|---|---|
| 27 yrs | — | ANA, a-SSA, a-SSB, a-U1RNP, hypocomplementaemia | Remission | Azathioprine, low-dose corticosteroid | 13.75 | 0 |
|
| ||||||
| 54 yrs | Gout, diabetes mellitus, COPD, ischemic heart disease | ANA, a-dsDNA, a-chromatin | Remission | Low-dose corticosteroid | 12.5 | 1 |
|
| ||||||
| 45 yrs | — | ANA, a -Sm, a-SSA, a-U1RNP, aCL IgM | Remission | — | 20 | 2 |
|
| ||||||
| 24 yrs | Raynaud's syndrome, Sjögren's syndrome, Hashimoto-thyroiditis, seronegative rheumatoid arthritis (erosive polyarthritis), idiopathic thrombocytopenic purpura | ANA, a-ENA, a-SSA, a-dsDNA, a-Sm, a-TPO | Remission | — | 10 | 0 |
|
| ||||||
| 33 yrs | Sjögren's syndrome | ANA, a-dsDNA, a-SSA, a-SSB, aCL IgM | Remission | — | 8.7 | 0 |
|
| ||||||
| 58 yrs | Sjögren's syndrome, | ANA, a-dsDNA, a-SSA, a-SSB, | Remission | — | 8.75 | 0 |
| type 2 diabetes mellitus | ||||||
|
| ||||||
| 57 yrs | Rheumatoid arthritis, sacroiliitis | ANA, a-ACPA, a-dsDNA, a-Sm, a-U1RNP | Remission | — | 7.5 | 0 |
|
| ||||||
| 29 yrs | Rheumatoid arthritis, asthma bronchial, aseptic femur-head necrosis, cataract, glaucoma | ANA, a-ACPA, a-dsDNA | Remission | — | 10 | 2 |
SLE: systemic lupus erythematosus, COPD: chronic obstructive pulmonary disease, ILD: interstitial lung disease, ANA: anti-nuclear antibody, a-SSA: anti-Sjögren's syndrome A antibody, a-SSB: anti-Sjögren's syndrome B antibody, a-chromatin: anti-chromatin antibody, anti-RNP: anti-ribonucleoprotein antibody, a-dsDNA: anti-double stranded deoxyribonucleic acid antibody, anti-Sm: anti-Smith antibody, aCL IgM: anti-cardiolipin antibody immunoglobulin M, a-U1RNP: anti-U1 ribonucleoprotein antibody, a-TPO: anti-thyreoid peroxidase antibody, MMF: mycophenolate mofetil, PED: prednisolone equivalent dose, and SLICC: systemic lupus international collaborating clinics.